24 December 2020 : Clinical Research
Comparison of Second- and Third-Generation Parathyroid Hormone Test Results in Patients with Chronic Kidney Disease
Magdalena Wójtowicz1ABCDEF, Wiesław Piechota1CDEF*, Zofia Wańkowicz2DEF, Jerzy Smoszna2DE, Stanisław Niemczyk2DEDOI: 10.12659/MSM.928301
Med Sci Monit 2020; 26:e928301
Table 1 Characteristics of the study group and the control group.
Study participants | Study group (n=205) | Control group (n=30: healthy volunteers) | ||
---|---|---|---|---|
Predialysis period (n=78: stage 3: 36 patients, stage 4: 35 patients, stage 5: 7 patients) | Hemodialyzed (n=95) | Peritoneal dialysis (n=32) | ||
Age (years) | 64±11 | 66±14 | 63±14 | 59±13 |
Sex (men/women) | 52/26 | 59/36 | 16/16 | 16/14 |
Medical history: | ||||
Causes of CKD | type 2 diabetes mellitus | Based on the interview: no history of kidney disease, diabetes, untreated or poorly controlled hypertension, hyperparathyroidism or hypoparathyroidism, taking vitamin D and/or calcium preparations | ||
23 patients – 29% | 21 patients – 22% | 9 patients – 28% | ||
Chronic glomerulonephritis | ||||
20 patients – 26% | 14 patients – 15% | 3 patients – 9% | ||
Hypertension | ||||
6 patients – 8% | 10 patients – 11% | 6 patients – 19% | ||
Polycystic kidney disease | ||||
3 patients – 4% | 4 patients – 4% | 3 patients – 9% | ||
Type 1 diabetes | ||||
4 patients – 5% | 4 patients – 4% | 1 patient – 3% | ||
Unknown or uncertain causes | ||||
7 patients – 9% | 21 patients – 22% | 5 patients – 16% | ||
Other and rare causes | ||||
15 patients – 19% | 21 patients – 22% | 5 patients – 16% | ||
Duration of dialysis treatment/number of patients | – | <12 months/32 | <12 months/8 | – |
1–<5 years/48 | 1–<5 years/20 | |||
5–10 years/12 | 5–10 years/2 | |||
>10 years/3 | >10 years/2 | |||
Blood samples were taken between January and December 2016. |